Your browser is no longer supported. Please, upgrade your browser.
Settings
CMPS [NASD]
COMPASS Pathways plc
Index- P/E- EPS (ttm)-1.73 Insider Own4.51% Shs Outstand35.93M Perf Week-6.12%
Market Cap1.38B Forward P/E- EPS next Y-2.08 Insider Trans0.00% Shs Float10.70M Perf Month-8.32%
Income-60.30M PEG- EPS next Q-0.47 Inst Own15.10% Short Float17.18% Perf Quarter-24.71%
Sales- P/S- EPS this Y-186.40% Inst Trans5.31% Short Ratio3.91 Perf Half Y-5.20%
Book/sh5.47 P/B6.23 EPS next Y-14.30% ROA- Target Price- Perf Year-
Cash/sh4.68 P/C7.27 EPS next 5Y- ROE- 52W Range22.51 - 61.69 Perf YTD-28.48%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-42.66% Beta-
Dividend %- Quick Ratio29.40 Sales past 5Y- Gross Margin- 52W Low57.15% ATR2.28
Employees61 Current Ratio29.40 Sales Q/Q- Oper. Margin- RSI (14)47.33 Volatility5.31% 6.16%
OptionableYes Debt/Eq0.00 EPS Q/Q-178.00% Profit Margin- Rel Volume1.34 Prev Close34.07
ShortableYes LT Debt/Eq0.00 EarningsMar 09 BMO Payout- Avg Volume470.69K Price35.38
Recom1.80 SMA20-0.46% SMA50-6.92% SMA200-15.01% Volume574,331 Change3.83%
Apr-01-21Initiated ROTH Capital Buy $88
Oct-14-20Initiated H.C. Wainwright Buy $65
Oct-13-20Initiated Evercore ISI Outperform
Oct-13-20Initiated Cowen Outperform
Oct-13-20Initiated Canaccord Genuity Buy $80
Oct-13-20Initiated Berenberg Buy $50
May-06-21 08:00AM  
May-03-21 03:01PM  
Apr-29-21 08:45PM  
08:23AM  
Apr-28-21 09:23AM  
06:43AM  
Apr-27-21 05:22PM  
04:43PM  
02:41PM  
Apr-21-21 04:01PM  
Apr-15-21 07:49AM  
03:00AM  
Apr-09-21 07:00AM  
Apr-01-21 07:01AM  
Mar-26-21 01:49PM  
11:56AM  
Mar-23-21 08:00AM  
Mar-18-21 02:36AM  
Mar-15-21 12:40PM  
Mar-12-21 11:43AM  
Mar-09-21 07:00PM  
07:00AM  
05:15AM  
Mar-03-21 07:20AM  
Mar-02-21 07:00AM  
Feb-27-21 06:50AM  
Feb-26-21 07:00AM  
Feb-25-21 08:30AM  
Feb-11-21 08:30AM  
Feb-09-21 07:02AM  
Feb-03-21 07:00AM  
Jan-28-21 08:00AM  
Jan-27-21 08:59AM  
Jan-26-21 12:51PM  
Jan-18-21 12:57PM  
Jan-16-21 09:38AM  
Jan-11-21 04:30PM  
Jan-08-21 01:19PM  
07:47AM  
07:47AM  
07:00AM  
Jan-06-21 07:30AM  
Jan-04-21 08:00AM  
Dec-28-20 09:02AM  
Dec-26-20 08:04AM  
Dec-21-20 08:00AM  
Dec-18-20 12:27AM  
Dec-16-20 03:19PM  
Nov-25-20 03:08PM  
Nov-24-20 08:30AM  
Nov-23-20 06:48PM  
Nov-15-20 08:26AM  
Nov-12-20 04:03PM  
07:02AM  
Nov-10-20 01:15PM  
Nov-09-20 09:50AM  
07:00AM  
Nov-05-20 07:00AM  
Nov-04-20 04:17PM  
09:20AM  
Oct-26-20 07:00AM  
Oct-16-20 02:55AM  
Sep-22-20 04:03PM  
Sep-18-20 04:19PM  
12:33PM  
Sep-17-20 10:40PM  
COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin formulation that is in Phase IIb clinical trial to treat patients with treatment-resistant depression. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is based in Cheshire, the United Kingdom.